Lorbrena (lorlatinib)

pCPA File Number: 21811
Negotiation Status:
Under consideration for negotiation
Indication(s):
Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
PC0249
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable